Thu, Apr 24, 2014, 9:46 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Oncothyreon Inc Message Board

  • avii77 avii77 Nov 19, 2012 8:06 AM Flag

    L-BLP25 vaccine plus letrozole for breast cancer

    Interesting paper out today. Merck is clearly setting their goals very high.

    "Finally, the goal of curing cancer with traditional therapy have virtually reached an impasse. The logical and potentially achievable goal of immunochemotherapy is to turn cancer from a lethal disease into a chronic condition."

    Now wouldn't that be something.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • AVII
      This Was My Message From September, 2012:

      L-BLP25 vaccine plus letrozole for breast cancer

      By bio77.Sep 21, 2012 4:25 AM.Permalink
      .

      L-BLP25 vaccine plus letrozole for breast cancer
      Is translation possible?
      OncoImConclusion
      The translational potential of our research
      will depend on a well-designed clinical
      trial considering factors that are typically controlled in preclinical settings
      (Fig. 1). Preclinical immunological studies are conducted in a pathogen-free
      environment, adhering to a rigid dose
      schedule and strict diet, serial monitoring
      of immune functions, and confirmation of
      the presence of tumor-associated antigens
      (TAAs) during therapy. The successful
      translation of our preclinical study to the
      clinic will depend on a number of different elements, including the age and tumor
      burden of patients at inclusion, the continuous monitoring of their immune system,
      the presence of TAAs, as well as the diet
      (which can affect immune responses) and
      possible co-medications (which also may
      alter the activity of L-BLP25). Clinically
      relevant endpoints such as overall survival
      vs. traditional measures of cytotoxic or
      hormonal drug activity need to be clearly the goal of curing cancer with traditional
      therapy have virtually reached an impasse.

      Finally, !!!!!!!
      And Here We Come !!!!!! The Whole Idea :
      The logical and potentially achievable
      goal of immunochemotherapy is to turn
      cancer from a lethal disease into a chronic
      condition
      OncoImmunology 1:9, 1–3; December 2012; © 2012 Landes Bioscience
      .
      0users liked this posts0users disliked this posts
      Reply

      They.Just Published Now ...

      • 2 Replies to bio77
      • Either way, thank you to both of you, usenmucin, and others who continue to post google searchable links to interesting papers and articles.

        This sentence taken from that paper --- In summary, commonly used chemotherapeutic agents have immunomodulatory properties that can be taken advantage of for augmenting the immune response to vaccines such as L-BLP25. --- is also telling and suggests a bright future for combination therapies with Stimuvax (assuming it works of course). Muc1 in particular is a fascinating area of research as it may be a big hitter and I'm sure others like me track down your articles and dive in. Thanks again...

        And speaking of Red, Ive read the papers that go back to the 1990's when Red and his associates at Biomira started following the muc1 immunotherapy trail. It's amusingly ironic that his team played a pivotal role in the cause and effect chain reaction that helped create ONTY and this board thereby drawing in the idiots that belittle him personally and diminish his contributions to this exciting area of cancer research.

      • My apologies Bio77. I thought your Sept post was referring to:

        "L-BLP25 vaccine plus letrozole induces a TH1 immune response and has additive antitumor activity in MUC1-expressing mammary tumors in mice." Clin Cancer Res 2012

        I see now that you shared in Sept an e-published ahead of print version of todays paper.

 
ONTY
2.89+0.01(+0.35%)Apr 24 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Apple Inc.
NasdaqGSThu, Apr 24, 2014 4:00 PM EDT
Baidu, Inc.
NasdaqGSThu, Apr 24, 2014 4:00 PM EDT